Corbus Pharmaceuticals Holdings (CRBP) Cash & Equivalents (2013 - 2025)

Corbus Pharmaceuticals Holdings' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $27.1 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents rose 123.36% year-over-year to $27.1 million in Q4 2025; TTM through Dec 2025 was $27.1 million, a 123.36% increase from a year earlier, with the FY2025 full-year figure at $27.1 million, up 123.36% from the prior year.
• Cash & Equivalents climbed to $27.1 million in Q4 2025 per CRBP's latest filing, from $25.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $66.6 million in Q1 2021 and bottomed at $1.7 million in Q2 2023.
• The 5-year median for Cash & Equivalents is $13.3 million (2022), against an average of $17.3 million.
• Biggest YoY gain for Cash & Equivalents was 4112.84% in 2021; the steepest drop was 93.92% in 2021.
• Year by year, Cash & Equivalents stood at $25.0 million in 2021, then tumbled by 32.01% to $17.0 million in 2022, then fell by 19.28% to $13.7 million in 2023, then declined by 11.46% to $12.2 million in 2024, then soared by 123.36% to $27.1 million in 2025.
• Per Business Quant, the three latest CRBP Cash & Equivalents figures stand at $27.1 million (Q4 2025), $25.5 million (Q3 2025), and $20.0 million (Q2 2025).